DNLI Stock Analysis: Denali Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 4.039m USD | 12M Return: 64.6% | US24823R1059 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 33.5M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 8.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Denali Therapeutics Inc. (NASDAQ: DNLI) is a U.S. biopharmaceutical company based in South San Francisco, California, that discovers and develops therapeutics targeting neurodegenerative and lysosomal storage diseases. Incorporated in 2013 and originally named SPR Pharma Inc., it adopted its current name in March 2015 and went public in December 2017.
The companys pipeline spans multiple programs, including the RIPK1 inhibitor Eclitasertib (SAR443122/DNL758) for peripheral inflammatory diseases, BIIB122/DNL151 (LRRK2 inhibitor) for Parkinsons disease, DNL593/TAK-594 for frontotemporal dementia-granulin, DNL126 for MPS IIIA (Sanfilippo Syndrome A), and DNL310 (Tividenofusp alfa), an enzyme replacement therapy for MPS II (Hunter Syndrome). Denali also advances proprietary Enzyme TransportVehicle (TV) and Oligonucleotide TV (OTV) platforms, with candidates in development for Pompe disease, Gaucher disease, Hurler syndrome (MPS I), Alzheimers disease, and Parkinsons disease.
As a clinical- and preclinical-stage biotechnology company, Denali operates a capital-intensive, pipeline-driven business model in which revenue typically depends on future drug approvals rather than current product sales, a common structure for firms in the biotechnology sub-industry focused on rare genetic and neurological disorders.
- DNL310 tividenofusp alfa pivotal data readout catalyst for Hunter Syndrome
- Sanofi collaboration milestone payments provide non-dilutive funding
- Cash burn rate and runway extension remain key investor concerns
| Net Income: -511.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.35 > 0.02 and ΔFCF/TA -2.18 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.37 > 3% & CFO -434.0m > Net Income -511.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.37 > 1.5 & < 3 |
| Outstanding Shares: last quarter (187.3m) vs 12m ago 9.25% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.31% > 50% (prev 0.0%; Δ 0.31% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.57 (Total Current Assets 753.9m - Total Current Liabilities 90.1m) / Total Assets 1.16b |
| B: -1.99 (Retained Earnings -2.31b / Total Assets 1.16b) |
| C: -0.44 (EBIT TTM -511.3m / Avg Total Assets 1.16b) |
| D: 2.59 (Book Value of Equity 835.2m / Total Liabilities 322.8m) |
| Altman-Z'' = -2.98 = D |
As of August 17, 2026, the stock is trading at USD 24.40 with a total of 846,243 shares traded. Over the past week, the price has changed by -1.73%, over one month by +7.35%, over three months by +32.61% and over the past year by +64.64%.
Current recommended Stop Loss: 23.00 (which is 5.7% or 1.3 ATR below the current price).
Denali Therapeutics has received a consensus analysts rating of 4.79. Therefore, it is recommended to buy DNLI.
- StrongBuy: 15
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 35.4 | 45.2% |
P/S = 1120.7947
P/B = 4.7848
Revenue TTM = 3.60m USD
EBIT TTM = -511.3m USD
EBITDA TTM = -497.3m USD
Long Term Debt = unknown (none)
Short Term Debt = 9.55m USD (from shortTermDebt, last fiscal year)
Debt = 59.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 32.2m
Net Debt = -650.8m USD (calculated: Debt 59.7m - CCE 710.5m)
Enterprise Value = 3.39b USD (4.04b + Debt 59.7m - CCE 710.5m)
Interest Coverage Ratio = unknown (Ebit TTM -511.3m / Interest Expense TTM 0.0)
EV/FCF = -8.28x (Enterprise Value 3.39b / FCF TTM -409.4m)
FCF Yield = -12.08% (FCF TTM -409.4m / Enterprise Value 3.39b)
FCF Margin = -11.4k% (FCF TTM -409.4m / Revenue TTM 3.60m)
Net Margin = -14.2k% (Net Income TTM -511.5m / Revenue TTM 3.60m)
Gross Margin = unknown ((Revenue TTM 3.60m - Cost of Revenue TTM 107.8m) / Revenue TTM)
Tobins Q-Ratio = 2.93 (Enterprise Value 3.39b / Total Assets 1.16b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 59.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -404.0m (EBIT -511.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.40 (Total Current Assets 753.9m / Total Current Liabilities 101.9m)
Debt / Equity = 0.07 (Debt 59.7m / totalStockholderEquity, last quarter 835.2m)
Debt / EBITDA = 1.31 (negative EBITDA) (Net Debt -650.8m / EBITDA -497.3m)
Debt / FCF = 1.59 (negative FCF - burning cash) (Net Debt -650.8m / FCF TTM -409.4m)
Total Stockholder Equity = 925.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -44.01% (Net Income -511.5m / Total Assets 1.16b)
RoE = -55.27% (Net Income TTM -511.5m / Total Stockholder Equity 925.3m)
RoCE = -47.88% (EBIT -511.3m / Capital Employed (Total Assets 1.16b - Current Liab 90.1m))
RoIC = -37.50% (negative operating profit) (NOPAT -404.0m / Invested Capital 1.08b)
WACC = 10.98% (E(4.04b)/V(4.10b) * Re(11.14%) + D(59.7m)/V(4.10b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.14% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 87.92 | Cagr: 10.57%
[DCF] Fair Price = unknown (Cash Flow -409.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.53 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.25 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.41 | Chg30d=+24.06% | Revisions=-50% | Analysts=16
EPS current Year (2026-12-31): EPS=-2.29 | Chg30d=+0.91% | Revisions=-17% | GrowthEPS=+22.8% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.43 | Chg30d=+2.03% | Revisions=-50% | GrowthEPS=-5.8% | GrowthRev=+106.3%
[Analyst] Revisions Ratio: -58% (up=1, down=8)